Cytori shares surge on mixed results for its PhI erectile dysfunction study
Shares of San Diego-based Cytori Therapeutics $CYTX bumped higher Monday morning on some mixed data for its regenerative cell therapy aimed at erectile dysfunction among a small group of patients with treatment-resistant cases of ED following radical prostatectomy.
There was a hit and a miss on a couple of key endpoints. Researchers say that the microcap biotech’s therapy scored a positive p value on the International Index of Erectile Function-5 (IIEF-5), but showed no change for the Erection Hardness Score (EHS) used by patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.